Michael Rybak, Pharm.D., M.P.H., Ph.D.

Michael Rybak, Pharm.D., M.P.H., Ph.D.

Professor

Office Location

EACPHS, Room 4148

Phone

313-577-4376

Email

m.rybak@wayne.edu

Department

Pharmacy Practice

Research website

https://orcid.org/0000-0003-2220-0081

Michael Rybak, Pharm.D., M.P.H., Ph.D.

Degrees and Certifications

Degrees

  • 2011-2016 - Ph.D., Public Health, Walden University
  • 1998-2005 - M.P.H., Wayne State University School of Medicine
  • 1979-1981 - Pharm.D., Wayne State University, Pharmacy
  • 1976-1979 - B.S., Northeastern University, Boston, Pharmacy
  • 1975-1976 - State University College of Buffalo, Buffalo, Biology
  • 1973-1975 - Associates Erie Community College, Amherst, Science

Certification

  • 2000 - Board Certified Pharmacotherapy Specialist 9/82. Added Qualifications for Infectious Diseases Pharmacotherapy 

Positions and Employment

  • 1993-Present - Professor of Pharmacy and Adjunct Professor of Medicine, Wayne State University
  • 2008-2011 - Associate Dean for Research, EACPHS, Wayne State University
  • 1987-1993 - Associate Professor, EACPHS, Wayne State University
  • 1981-1987 - Assistant Professor of Pharmacy Practice 

Awards and Honors

  • 2022 - Academy of Scholars, Wayne State University
  • 2019 - Distinguished Investigator Award, American College of Clinical Pharmacy, Infectious Diseases Practice Network
  • 2018 - Charles H. Gershenson Distinguished Faculty Fellows Award, Wayne State University
  • 2018 - Van Greene Lecture Award, Mercer University College of Pharmacy 
  • 2017 - Fellow Recognition Award, Society of Infectious Diseases Pharmacists
  • 2016 - Therapeutics Frontiers Lecture Award, American College of Clinical Pharmacy 
  • 2013 - Preceptor for the Outstanding Student Poster Award in Clinical Sciences, Wayne State University
  • 2011 - Outstanding Achievement in Clinical Sciences Research Award, Eugene Applebaum College of Pharmacy & Health Sciences
  • 2011 - Lead Industry Collaborator Award, Wayne State University
  • 2007 - American College of Clinical Pharmacy-Ortho-McNeil Infectious Diseases Fellowship Award
  • 2005 - Distinguished Alumni Award, Wayne State University
  • 2004 - The Russell R. Miller Award for Recognition of Sustained and Outstanding Contributions to the Literature of Clinical Pharmacy
  • 2003 - The Ted Goldberg Prize in Community Health, School of Medicine, Wayne State University
  • 2003 - American College of Clinical Pharmacy-Merck Infectious Diseases Fellowship Award
  • 2002 - American Society of Health-System Pharmacists, Award for Sustained Literature Contributions to the Pharmacy Literature for ASHP
  • 2000 - Impact paper in ID Pharmacists Research Award, Society of Infectious Diseases Pharmacists
  • 1997 - Distinguished Faculty Fellowship Award, Wayne State University
  • 1996 - Fellow, Infectious Disease Society of America
  • 1992 - Wayne State University Career Chair Development Award
  • 1992 - R.W. Johnson Research Institute Fellowship Award
  • 1991 - Wayne State University Academic Achievement Award for Natural Sciences
  • 1991 - American College of Clinical Pharmacy Fellow Recognition Award
  • 1990 - Merck Foundation Fellowship Award
  • 1990 - The Upjohn Pharmacy Research Award, Michigan Society of Hospital Pharmacists

Professional Memberships

  • 2016-Present - Honors and Awards Committee Roster and Charges
  • 2008-Present - European Society of Clinical Microbiology and Infectious Diseases
  • 2005-Present - Society of Healthcare Epidemiology of America
  • 2003-Present - ASHP Research Foundation
  • 2000-Present - Michigan Antibiotic Resistance Committee
  • 1998-Present - Alliance for the Prudent Use of Antibiotics
  • 1991-Present - Infectious Diseases Society of America
  • 1990-Present - Society of Infectious Diseases Pharmacists
  • 1990-Present - Michigan Society of Hospital Pharmacists
  • 1990-1993 - FDA - Regional Task Force on AIDS Fraud
  • 1989-Present - American Society of Microbiology
  • 1985-1987 - Board Liaison to Membership Committee
  • 1985-1987 - Southeastern Society of Hospital Pharmacists Board of Directors
  • 1984-1985 - Program and Seminar Committee
  • 1983-1987 - Michigan Board of Pharmacy - Internship Committee
  • 1983-Present - Phi Delta Chi Pharmaceutical Fraternity
  • 1982-Present - American College of Clinical Pharmacy
  • 1982-Present - American Association of Colleges of Pharmacy
  • 1982-1987 - American Society of Hospital Pharmacists
  • 1981-Present - Rho Chi Pharmaceutical Honor Society
  • 1981-Present - American Society of Health-System Pharmacists
  • 1981-Present - Southeastern MI Society of Hospital Pharmacists
  • 1976-1979 - Massachusetts Society of Hospital Pharmacists

Primary Research Interest

  • Dr. Rybak’s primary focus of research is antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious diseases health outcomes, including their relationship to bacterial resistance. His most recent work is focused on the laboratory and clinical outcomes assessment of combination therapy for methicillin and vancomycin-resistant Staphylococcus aureus, enterococcus and gram-negative pathogens.

Recent Publications

Co-Authored Chapters (Last 3 Years)

  • Morrisette T, Rybak MJ. Detection of VRSA, VISA, and Vancomycin-Heteroresistant Staphylococcus aureus (hVISA). American Society of Microbiology’s Clinical Microbiology Procedures Handbook. Accepted. Anticipated publication date: fall 2022.

Refereed Journals (Last 3 Years)

  • Kebriaei RK, Lehman SM, Shah RM, Stamper KC, Kunz Coyne AJ, Holger D, El Ghali A, Rybak MJ. Phage-antibiotic Combination Optimization against Biofilms of Staphylococcus aureus: Empirical Screening Approach. Spectrum (2023). Accepted for publication.
  • El Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. Sulbactam-durlobactam: a novel combination of β-lactamase inhibitors for the treatment of carbapenem-resistant Acinetobacter spp. Infections. Pharmacotherapy (2023).
  • Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ. Evaluation of omadacycline alone and in combination with rifampin against biofilm-producing Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy (2023). Accepted for publication.
  • Gomes MZR, de Lima EM, Aires CAM, Pereira PS, Yim J, Silva FH, Rodrigues CAS, Oliveira TRT, da Silva PP, Eller CM, de Souza CMR, Rybak MJ, Albano RM, de Miranda AB, Machado E, Catanho M, Nucleus of Hospital Research (NPH) study collaborators. Outbreak report of polymyxin- carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes. Nature, Scientific Reports (2023).
  • Mishra N, Abdelhady W, Elsayed A, Lapitan C, Proctor R, Rybak MJ, Miro J, Bayer A. Combinations of Daptomycin Plus Ceftriaxone, but not Ascending Daptomycin Dose-Regimens, are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance. Antimicrobial Agents and Chemotherapy (2023).
  • Kunz Coyne Ak, El Ghali A, Lucas K, Witucki P, Rebold N, Holger D, Veve MP, Rybak MJ. High Dose Cefepime Versus Carbapenems for Bacteremia Caused by Enterobacterales with Moderate to High Risk of Clinically Significant AmpC b-Lactamase Production. Open Forum Infectious Diseases (2023).
  • Caniff KE, Rebold N, Rybak MJ. Oral stepdown in Gram-positive bloodstream infections: A step in the right direction. Pharmacotherapy (2023). Accepted for publication.
  • Rebold N, Lagnf A, Alosaimy S, Holger D, Witucki P, Mannino A, Dierker M, Lucas K, Kunz Coyne AJ, El Ghali A, Caniff K, Veve M, Rybak MJ. Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure. Microbiology Spectrum (2022).
  • Kebriaei R, Bayer AS, Lapitan CK, Rybak MJ, Somerville GA, Mishra NK. Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and In an Ex Vivo Model.Antibiotics (2022).
  • Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins III NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiology Spectrum (2022).
  • Zasowski EJ, Trinh TD, Claeys KC, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Pulido Cejudo A, Melo L, Rybak MJ. International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. Infectious Diseases and Therapy (2022).
  • Kunz Coyne AJ, Stamper K, Kebriaei R, Holger DJ, El Ghali A, Morrisette T, Biswas B, Wilson M, Deschenes MV, Canfield GS, Duerkop BA, Arias CA, Rybak MJ. Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-embedded Multidrug-resistant Enterococcus faecium with Preserved Phage Susceptibility. Antibiotics (2022).
  • Holger D., Rebold N. S., Alosaimy S., Morrisette T., Lagnf A., Belza A. C., Kunz Coyne A. J., El Ghali A., Veve M., Rybak M. J. Impact of Ceftolozane-tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infectious Diseases and Therapy (2022).
  • Blaskovich M.A.T., Hansford K. A., Butler M. S., et al…, Rybak M.J….. Cooper M.A. A Promising Membrane-targeting Lipoglycopeptide Antibiotic to Treat Gram-Positive Biofilm-Related Infections. Science and Translational Medicine.14, eabj2381 (2022).
  • Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, et al… Rybak MJ. Nephrotoxicity of Vancomycin in Combination with Beta-lactam Agents: Ceftolozane-tazobactam vs. Piperacillin-tazobactam. Clinical Infectious Disease (2022).
  • Holger D, Lev KL, Kebriaei R, Morrisette T, Shah R, Alexander J, Lehman SM, Rybak MJ. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: in vitro synergy testing. Journal of Applied Microbiology (2022).
  • Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-World, Multi-Center Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. Infectious Diseases and Therapy (2022).
  • Rebold N, Alosaimy S, Morrisette T, Holger D, Lagnf AM, Ansari I, Belza AC, Cheaney L, Hussain H, Herbin S, Abdul-Mutakabbir J, Carron C, Sandhu A, Chopra T, Rybak MJ. Clinical characteristics associated with bacterial bloodstream coinfection in COVID-19. Infectious Diseases and Therapy (2022).
  • Kebriaei R, Lev KL, Shah RM, Stamper KC, Holger DJ, Morrisette T, Kunz Coyne AJ, Lehman, SM, Rybak MJ. Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination. Microbiology Spectrum (2022).
  • Gina A. Suh, Thomas P. Lodise, Pranita D. Tamma, Jane M. Knisely, Jose Alexander, Saima Aslam, Karen D. Barton, Erica Bizzell, Katherine M. C. Totten, Joseph L. Campbell, Benjamin K. Chan, Scott A. Cunningham, Katherine E. Goodman, Kerryl E. Greenwood-Quaintance, Anthony D. Harris, Shayla Hesse, Anthony Maresso, Veronique Nussenblatt, David Pride, Michael J. Rybak, Zoe Sund, David van Duin, Daria Van Tyne, Robin Patel, for the Antibacterial Resistance Leadership Group. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrobl Agents Chemoth, 2022.
  • Lev K,. Kunz Coyne AJ, Kebriaei R, Morrisette T, Stamper K, Holger D, Canfield GS, Duerkop BA Arias CA, Rybak MJ. Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-embedded MDR Enterococcus faecium. Antibiotics (2022).
  • Dana J Holger, Ashlan J Kunz Coyne, Jing J Zhao, Avnish Sandhu, Hossein Salimnia, Michael J Rybak. Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report, Open Forum Infectious Diseases, 2022;, March 5, 9(4):
  • Rebold N, Lodise T, Rybak MJ. Panacea or oversimplification: Relating AUC and troughs. Am J Health Syst Pharm. 2022 Feb 5:zxac031.
  • Kunz Coyne, A.J., El Ghali, A., Holger, D. Rebold, N., Rybak, MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther (2022).
  • Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Bhatia S, Klinker KP, Veve MP, Estrada SJ, Johns ST, Sawyer AJ, Huang V, LaFrance B, Levine DP, Kaye KS, Davis SL, Rybak MJ. Multicenter cohort study of ceftarolione versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. Dec 23, 2021.
  • Rebold N, Morrisette T, Lagnf AM, Alosaimy S, Holger D, Barber K, Justo JA, Antosz K, Carlson TJ, Frens JJ, Biagi M, Kufel WD, Moore WJ, Mercuro N, Raux BR, Rybak MJ. Early multicenter experience with imipenem-cilastin-relebactam for multidrug-resistant gram-negative infections. Open Forum Infect Dis. 2021. Dec 9, 8(12): ofab554. doi: 10.1093/ofid/ofab554. eCollection 2021 Dec. PMID: 34901302.
  • Vanamala K, Bhise K, Sanchez H, Kebriaei R, Luong D, Sau S, Abdelhady H, Rybak MJ, Andes D, Iyer AK. Folate functionalized lipid nanoparticles for targeted therapy of methicillin-resistant Staphylococcus aureus. Pharmaceutics. 2021. Oct 26, 13(11):1791.
  • Morrisette T, Lev KL, Canfield GS, Duerkop BA, Kebriaei R, Stamper KC, Holger D, Lehman SM, Willcox S, Arias CA, Rybak MJ. Evaluation of bacteriophage cocktails alone and in combination with daptomycin against daptomycin-nonsusceptible Enterococcus faecium. Antimicrob Agent Chemother. 2021. Nov1:AAC016321.
  • Barber KE, Shmamout Z, SmithJR, Kebriaei R, Morrisette T, Rybak MJ. Biofilm time-kill curves to assess the bactericidal activity of daptomycin combinations against biofilm-producing vancomycin-resistant Enterococcus faecium and faecalis. Antibiotics (Basel). 2021. July23;10(8):897.
  • Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, Marco R Scipione, Jing J Zhao, Sarah C J Jorgensen, Ryan Mynatt, Travis J Carlson, Jinhee Jo, Kevin W Garey, David Allen, Kailynn DeRonde, Ana D Vega, Lilian M Abbo, Veena Venugopalan, Vasilios Athans, Stephen Saw, Kimberly C Claeys, Mathew Miller, Kyle C Molina, Michael Veve, Wesley D Kufel, Lee Amaya, Christine Yost, Jessica Ortwine, Susan L Davis, Rybak MJ. Real-world, Multi-Center Experience with Meropenem-Vaborbactam for Gram-Negative Bacterial Infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, Open Forum Infectious Diseases, 2021.
  • Holger D, Kebriaei R, Morrisette T, Lev K, Alexander J, Rybak MJ. Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics (Basel). 2021 May 11;10(5):556.
  • Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, Sarah C J Jorgensen, Trang D Trinh, Evan J Zasowski, Marco R Scipione, Jing J Zhao, Ryan Mynatt, Shelbye Herbin, Sorabh Dhar, Teena Chopra, James Janisse, Nicholas Rebold, Jason M Pogue, Rybak MJ. Standardized Treatment and Assessment Pathway Improves Mortality in Adults with Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH-Study, Open Forum Infectious Diseases, 2021.
  • W Justin Moore, Andrew Webb, Taylor Morrisette, Louisa K Sullivan, Sara Alosaimy, Shahrier Hossain, Zachary Howe, Olga O Vlashyn, Frank P Paloucek, DABAT, Rybak MJ, Sheila Wang. Impact of COVID-19 pandemic on training of pharmacy residents and fellows: Results from a national survey of postgraduate pharmacy trainees, American Journal of Health-System Pharmacy, 2021.
  • Rebold, N., Holger, D., Morrisette, T., Alosaimy, S., Rybak MJ. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. Infect Dis Ther (2021).
  • Morrisette T, Alosaimy S, Philley JV, Wadle C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002.

Refereed Papers (Year-To-Date)

  • A. El Ghali, AJ Kunz Coyne, K. Lucas, P. Witucki, S. Nuzha, N. Bhutani, M. Veve, MJ. Rybak. Renal dose adjustment of β-lactam-β-lactamase inhibitors associated with increased risk of mortality in respiratory tract or bloodstream infections. 25th Annual Making a Difference in Infectious Disease (MAD-ID) Meeting. Orlando. Florida, 5/10/23-5/13/23.
  • CR. Bleick, K. Stamper, S. Mohib, A. Avery, S. Lehman, MJ. Rybak. Impact of bacteriophage Sb-1 alone or combined antimicrobial peptide LL-37 against methicillin-resistant S. aureus. March 2023. Michigan American Society for Microbiology (MI-ASM) at Oakland University.
  • AJ. Kunz Coyne, K. Lucas, P. Witucki, C. Bleick, J. Truong, J. Andrade, J. Cerenzio, M. Biagi, M. Todd, M. Verve, MJ. Rybak. Early Administration of Ceftazidime-Avibactam for MDR-P. aeruginosa Pneumonia Increases Clinical Success Rates. March 2023. Graduate Research Symposium at Wayne State University.
  • AJ. Kunz Coyne, K. Stamper, R. Kebriaei, C. Bleick, S. Lehman, MJ. Rybak. Bacteriophage-Antibiotic Combinations Against MRSA Demonstrate Bactericidal Activity in Biofilm Models. March 2023. Graduate Research Symposium at Wayne State University.
  • AJ. Kunz Coyne, K. Stamper, R. Kebriaei, A. Bayer, S. Lehman, MJ. Rybak. Phage-Daptomycin Combination in Simulated Endocardial Vegetation Model: Eradication of High MRSA Bacterial Load and Preservation of Phage Sensitivity. March 2023. Graduate Research Symposium at Wayne State University.
  • KE. Caniff, K. Lucas, MJ. Rybak. Comparison of ceftaroline monotherapy vs combination therapy for treatment of refractory methicillin-resistant Staphylococcus aureus bloodstream infection. March 2023. Graduate Research Symposium at Wayne State University.
  • A. El Ghali, K. Stamper, D. Holger, J. Alexander, S. Lehman, MJ. Rybak. Phage-antibiotic Combinations Eradicate XDR Pseudomonas aeruginosa in 4-day Ex-Vivo Simulated Endocardial Vegetation Models. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • A. El Ghali, S. Alosaimy, T. Morrisette, R. Vemula, J. Philley, C. Meija-Chew, Y. Hamad, R. Stevens, J. Zeuli, R. Hasbun, S. Butt, T. Gore, K. Molina, M. Thomas, C. Fiske, A. Simonyan, C. Cimino, E. Kaip, J. Frens, M. Barger, A. Ong, GM. Cabanilla, K. Lucas, P. Witucki, MJ. Rybak. A Multi-center Evaluation of Treatment Durability and Safety of Omadacycline for Mycobacterium abscessus infections. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • KE. Caniff, N. Rebold, K. Lucas, Y. Guo, M. Chang, N. Tran, KE. Barber, A. Carr, J. Hayes, M. Biagi, J. Frens, TJ. Carlson, R. Li, JA. Justo, K. Antosz, WD. Kufel, R. Benefield, JW. Moore, J. Ross, A. Hobbs, S. Stefanos, N. Mercuro, B. Raux, K. Zeitler, MJ. Rybak. Real-world, multicenter experience with imipenem-cilastatin-relebactam for infections due to Pseudomonas aeruginosa. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • KE. Caniff, K. Lucas, MJ. Rybak. Comparison of ceftaroline monotherapy vs combination therapy for treatment of refractory methicillin-resistant Staphylococcus aureus bloodstream infection. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • AJ. Kunz Coyne, K. Lucas, P. Witucki, C. Bleick, J. Truong, J. Andrade, J. Cerenzio, M. Biagi, M. Todd, M. Veve, MJ. Rybak. Early Administration of Ceftazidime-Avibactam for MDR-P. aeruginosa Pneumonia Increases Clinical Success Rates. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • AJ. Kunz Coyne, K. Stamper, R. Kebriaei, C. Bleick, S. Lehman, MJ. Rybak. Bacteriophage-Antibiotic Combinations Against MRSA Demonstrate Bactericidal Activity in Biofilm Models. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • AJ. Kunz Coyne, K. Stamper, R. Kebriaei, A. Bayer, S. Lehman, MJ. Rybak. Phage-Daptomycin Combination in Simulated Endocardial Vegetation Model: Eradication of High MRSA Bacterial Load and Preservation of Phage Sensitivity. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.
  • MZR. Gomes, PP. da Silva, EM de Lima, J. Yim, FH. Silva, CAS. Rodrigues, MJ. Rybak, RM. Albano, AB de Miranda, E. Machado, M. Catanho. Geographical information system for monitoring polymyxin-carbapenem-resistant Klebsiella pneumoniae causing intractable infections in a hospital: outbreak surveillance with whole-genome sequencing. April 2023. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Hybrid Meeting.

Laboratory Web Site

http://cphs.wayne.edu/research/anti-infective-lab.php

Courses taught by Michael Rybak, Pharm.D., M.P.H., Ph.D.

Winter Term 2024 (current)

Winter Term 2023

← Return to listing